Clinical Trial Update: Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of SHR-2010 Injection in primary IgA nephropathy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• SHR-2010 Injection (SHR-2010)

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: Primary IgA Nephropathy | Phase 2 | Status: TERMINATED